Evidence map›Paper›PMID 32483759›Full record

ArticleDoklady. Biochemistry and biophysics2020

Blockers of Nicotinic Acetylcholine Receptors Delay Tumor Growth and Increase Antitumor Activity of Mouse Splenocytes.

T I Terpinskaya, A V Osipov, T V Balashevich, T L Yanchanka, E A Tamashionik, V I Tsetlin, Yu N Utkin

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Marine drugs · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

T I TerpinskayaInstitute of Physiology, National Academy of Sciences of Belarus, Minsk, Belarus.
A V OsipovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. osipov-av@ya.ru.
T V BalashevichInstitute of Physiology, National Academy of Sciences of Belarus, Minsk, Belarus.
T L YanchankaInstitute of Physiology, National Academy of Sciences of Belarus, Minsk, Belarus.
E A TamashionikInstitute of Physiology, National Academy of Sciences of Belarus, Minsk, Belarus.
V I TsetlinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Yu N UtkinShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Institute of Physiology National Academy of Sciences of Belarus · BYInstitute of Bioorganic Chemistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blockade of α6, α3β2, α9α10, and α7 subtypes of nicotinic acetylcholine receptors slows tumor growth in vivo, increases cytotoxic activity of splenocytes from tumor-bearing mice, and, to some extent, reduces the viability of Ehrlich carcinoma cells in vitro. These data indicate that nicotinic acetylcholine receptors are involved in oncogenesis, affecting the survival of tumor cells, inter alia, via modulation of the antitumor immunity.

Indexed as

alpha7 Nicotinic Acetylcholine ReceptorAnimalsAntineoplastic AgentsCarcinogenesisCarcinoma, Ehrlich TumorCell ProliferationCell SurvivalConotoxinsMiceNeoplasm TransplantationNicotinic AntagonistsReceptors, NicotinicSpleenalpha7 Nicotinic Acetylcholine ReceptorAntineoplastic AgentsChrna9 protein, mouseConotoxinsNicotinic Antagonistsnicotinic receptor alpha3beta2nicotinic receptor alpha6Receptors, NicotinicEhrlich carcinomaneurotoxinsnicotinic receptorssplenocytes

Identifiers

PMID32483759
OpenAlexW3030541590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.